Silverback Therapeutics (Silverback Therapeutics) 6-1 Month Momentum % : 73.84% (As of May. 08, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silverback Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-08), Silverback Therapeutics's 6-1 Month Momentum % is 73.84%.

The industry rank for Silverback Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

SBTX's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: -0.39 vs SBTX: 73.84

Competitive Comparison of Silverback Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Silverback Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silverback Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silverback Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Silverback Therapeutics's 6-1 Month Momentum % falls into.

Silverback Therapeutics (NAS:SBTX) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Silverback Therapeutics (NAS:SBTX) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Silverback Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Silverback Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Silverback Therapeutics (Silverback Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silverback Therapeutics Inc (NAS:SBTX) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Fairview Avenue N, Suite 600, Seattle, WA, USA, 98109

Website

https://www.silverbacktx.com

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Executives

Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Pratik Shah Living Trust Dated June 15, 2011	10 percent owner	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Michael Kelly	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Rajeev Dadoo	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Sarina Tanimoto	10 percent owner, officer: Chief Medical Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Eric Karas	officer: Chief Commercial Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma	officer: Chief Business Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal	director, 10 percent owner, officer: President and CEO	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Pratik Shah	director, 10 percent owner	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017